|
⚲
|
| Keyboard |
| Azitra Inc | |
|---|---|
| Ticker | AZTR |
| CIK # | 0001701478 |
| CUSIP | 05479L203 |
| Sector | Life Sciences - Pharmaceutical Preparations |
| Address | 21 Business Park Drive, Suite 6, Branford, CT 06405 |
| Source | [EDGAR] |
| Reg D Offering (Form D) | Filed | Raised | Terms |
|---|---|---|---|
| Azitra Inc | 2022-10-12 | 4.3 M | Exemption: 506(b) · Remaining: $150,000 · Duration: One year or less · Revenue: Decline to Disclose |
| CIK | Filing | 2011 - 2026 |
|---|---|---|
| [0001701478] | 10-K | |
| [0001701478] | 10-Q | |
| [0001701478] | 3 | |
| [0001701478] | 4 | |
| [0001701478] | 8-K | |
| [0001701478] | D | |
| [0001701478] | SC 13D | |
| [0001701478] | SC 13G |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed | % Owned |
|---|---|---|---|
| Dauntless Investment Group LLC | Azitra Inc | [2026-06-25] | 0.0 |
| Salva Francisco D | Azitra Inc | [2026-06-24] | 0.0 |
| Stonepine Capital Management LLC | Azitra Inc | [2026-06-22] | 0.0 |
| Alumni Capital LP | Azitra Inc | [2025-08-20] | 0.0 |
| Ayrton Capital LLC | Azitra Inc | [2025-05-14] | 0.0 |
| CVI Investments Inc | Azitra Inc | [2024-08-01] | 8.0 |
| L1 Capital Global Opportunities Master Fund Ltd | Azitra Inc | [2024-07-29] | 0.99 |
| Lytton Laurence W | Azitra Inc | [2024-02-27] | 5.8 |
| Alpha 18 Inc | Azitra Inc | [2024-02-26] | 5.2 |
| Bayer Healthcare LLC | Azitra Inc | [2024-02-12] | 10.8 |
| BIOS Equity Partners LP | Azitra Inc | [2023-07-03] | 6.6 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Salva Francisco D
Series B Warrants · derivative
|
2026-03-18 | Buy | 4,064,050 | ||
|
Salva Francisco D
Series C Warrants · derivative
|
2026-03-18 | Buy | 4,064,050 | ||
|
Salva Francisco D
Series A Convertible Non-Redeemable Preferred Stock · derivative
|
2026-03-18 | Buy | 500 | ||
|
Schroer John R
Stock Options (Right To Buy) · derivative
|
2025-12-19 | Grant | 3,003 | $0.00 | |
|
Salva Francisco D
Stock Options (Right To Buy) · derivative
|
2025-12-19 | Grant | 59,309 | $0.00 | |
|
Whitfill Travis
Stock Options (Right To Buy) · derivative
|
2025-12-19 | Grant | 23,724 | $0.00 | |
|
Ryan Barbara
Stock Options (Right To Buy) · derivative
|
2025-12-19 | Grant | 3,003 | $0.00 | |
|
Staskey Norm
Stock Options (Right To Buy) · derivative
|
2025-12-19 | Grant | 15,015 | $0.00 | |
|
Staskey Norm
Common Stock
|
2024-03-29 | Buy | 47,600 | $0.21 | 9,996 |
|
Whitfill Travis
Common Stock
|
2024-02-13 | Buy | 15,000 | $0.30 | 4,500 |
|
Staskey Norm
Common Stock
|
2024-02-13 | Buy | 3,300 | $0.30 | 990 |
|
Salva Francisco D
Common Stock
|
2024-02-13 | Buy | 333,300 | $0.30 | 99,990 |
|
Schroer John R
Stock Options (Right To Buy) · derivative
|
2023-09-08 | Grant | 10,000 | $0.00 | |
|
Staskey Norm
Stock Options (Right To Buy) · derivative
|
2023-09-08 | Grant | 10,000 | $0.00 | |
|
Ryan Barbara
Stock Options (Right To Buy) · derivative
|
2023-09-08 | Grant | 10,000 | $0.00 | |
|
Whitfill Travis
Stock Options (Right To Buy) · derivative
|
2023-09-08 | Grant | 10,000 | $0.00 | |
|
Bayer Aktiengesellschaft +3
Common Stock
|
2023-06-21 | Conversion | 1,307,401 | ||
|
Bayer Aktiengesellschaft +3
Series B Convertible Preferred Stock · derivative
|
2023-06-21 | Conversion | 1,307,401 | $0.00 | |
|
Common stock, $0.0001 par value
|
2023-06-21 | Conversion | 42,437 | ||
|
Common stock, $0.0001 par value
|
2023-06-21 | Conversion | 249,474 | ||
| showing 20 of 94 most recent transactions | |||||
| 13F Ownership Over Time | Holders | Shares Held |
|---|---|---|
| 2026-03-31 | 7 | 540,487 |
| 2025-12-31 | 9 | 225,433 |
| 2025-09-30 | 5 | 42,284 |
| 2025-06-30 | 7 | 402,257 |
| 2025-03-31 | 12 | 533,292 |
| 2024-12-31 | 11 | 255,943 |
| 2024-09-30 | 8 | 137,215 |
| 2024-06-30 | 9 | 596,319 |
| 2024-03-31 | 13 | 1,539,827 |
| 2023-12-31 | 6 | 47,327 |
| 2023-09-30 | 9 | 182,271 |
| 2023-06-30 | 5 | 136,159 |
| Form 13F Holdings | ||||
|---|---|---|---|---|
| Firm | Period | DFND | Voting | Shares | Prev | Page 1 | Next |